Roche: positive results in leukemia
(CercleFinance.com) - Roche announced at the weekend that a Phase 3 study of Venclexta/Venclyxto, its new blood cancer treatment, has shown positive results in acute myeloid leukemia, the most common type of leukemia today.
According to the Swiss laboratory, the combination of Venclexta/Venclyxto with Celgene's azacitidine reduced the risk of death by 34% compared to patients treated with azacitidine alone, with an average survival of 14.7 months compared to 9.6 months for the reference treatment.
The addition of Venclexta/Venclyxto to azacitidine also resulted in an improved remission rate of 66.4% compared to 28.3% in the azacitidine group.
This data was unveiled at the European Haematology Association (EHA) congress, held virtually for the first time in its history.
Copyright (c) 2020 CercleFinance.com. All rights reserved.
According to the Swiss laboratory, the combination of Venclexta/Venclyxto with Celgene's azacitidine reduced the risk of death by 34% compared to patients treated with azacitidine alone, with an average survival of 14.7 months compared to 9.6 months for the reference treatment.
The addition of Venclexta/Venclyxto to azacitidine also resulted in an improved remission rate of 66.4% compared to 28.3% in the azacitidine group.
This data was unveiled at the European Haematology Association (EHA) congress, held virtually for the first time in its history.
Copyright (c) 2020 CercleFinance.com. All rights reserved.